{"nctId":"NCT00918879","briefTitle":"Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control","startDateStruct":{"date":"2009-05"},"conditions":["Type 2 Diabetes"],"count":213,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Saxagliptin"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Saxagliptin","otherNames":["Onglyza"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosed with Type 2 diabetes\n* Patients should be drug naïve ie, not received medical treatment for diabetes\n* HbA1c ≥ 7.2% and ≤10.0% (at enrolment), HbA1c ≥ 7.0% and ≤10.0% (at randomization)\n\nExclusion Criteria:\n\n* Insulin therapy within one year of enrolment (with the exception of insulin therapy during a hospitalization or use in gestational diabetes)\n* Type 1 diabetes,history of ketoacidosis or hyperosmolar non-ketonic koma","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c)","description":"Adjusted\\* mean change from baseline in glycosylated haemoglobin A1c (HbA1c) achieved with saxagliptin 5 mg versus placebo at Week 24 (LOCF, Full Analysis set). HbA1c is a continuous measure, the change from baseline for each subject is calculated as the Week 24 values minus the baseline value. HbA1c data were excluded on and after rescue medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.33","spread":"0.080"},{"groupId":"OG001","value":"8.33","spread":"0.072"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.82","spread":"0.116"},{"groupId":"OG001","value":"8.28","spread":"0.114"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.51","spread":"0.098"},{"groupId":"OG001","value":"-0.05","spread":"0.098"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG)","description":"Adjusted\\* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 5 mg versus placebo at Week 24 (LOCF, Full Analysis set). FPG is a continuous measure, the change from baseline for each subject is calculated as the Week 24 values minus the baseline value. FPG data were excluded on and after rescue medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"150.77","spread":"3.569"},{"groupId":"OG001","value":"151.35","spread":"3.693"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"140.58","spread":"3.326"},{"groupId":"OG001","value":"151.02","spread":"4.833"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.35","spread":"3.827"},{"groupId":"OG001","value":"-0.16","spread":"3.863"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG)","description":"Adjusted\\* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 5 mg versus placebo at Week 24 (LOCF, Full Analysis set). FPG is a continuous measure, the change from baseline for each subject is calculated as the Week 24 values minus the baseline value. FPG data were excluded on and after rescue medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.37","spread":"0.198"},{"groupId":"OG001","value":"8.40","spread":"0.205"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.80","spread":"0.185"},{"groupId":"OG001","value":"8.38","spread":"0.268"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.58","spread":"0.212"},{"groupId":"OG001","value":"-0.00","spread":"0.214"}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients (Expressed in Percentage of Total Participants) Achieving a Therapeutic Glycemic Response Defined as HbA1c < 7.0% at Week 24","description":"Proportion of participants (expressed in percentage of total participants)achieving HbA1c \\< 7.0% for saxagliptin versus placebo at Week 24 (LOCF, Full Analysis set). HbA1c data were excluded on and after rescue medication","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.1","spread":null},{"groupId":"OG001","value":"13.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":107},"commonTop":["Urinary Tract Infection"]}}}